The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold
Open accessAbstract
Nanobodies, single-domain antigen-binding fragments of camelid-specific heavy-chain only antibodies offer special advantages in therapy over classic antibody fragments because of their smaller size, robustness, and preference to target unique epitopes. A Nanobody differs from a human heavy chain variable domain in about ten amino acids spread all over its surface, four hallmark Nanobody-specific amino acids in the framework-2 region (positions 42, 49, 50, and 52), and a longer third antigen-binding loop (H3) folding over this area. For therapeutic applications the camelid-specific amino acid sequences in the framework have to be mutated to their human heavy chain variable domain equivalent, i.e. humanized. We performed this humanization exercise with Nanobodies of the subfamily that represents close to 80% of all dromedary-derived Nanobodies and investigated the effects on antigen affinity, solubility, expression yield, and stability. It is demonstrated that the humanization of Nanobody-specific residues outside framework-2 are neutral to the Nanobody properties. Surprisingly, the Glu-49 → Gly and Arg-50 → Leu humanization of hallmark amino acids generates a single domain that is more stable though probably less soluble. The other framework-2 substitutions, Phe-42 → Val and Gly/Ala-52 → Trp, are detrimental for antigen affinity, due to a repositioning of the H3 loop as shown by their crystal structures. These insights were used to identify a soluble, stable, well expressed universal humanized Nanobody scaffold that allows grafts of antigen-binding loops from other Nanobodies with transfer of the antigen specificity and affinity. Nanobodies, single-domain antigen-binding fragments of camelid-specific heavy-chain only antibodies offer special advantages in therapy over classic antibody fragments because of their smaller size, robustness, and preference to target unique epitopes. A Nanobody differs from a human heavy chain variable domain in about ten amino acids spread all over its surface, four hallmark Nanobody-specific amino acids in the framework-2 region (positions 42, 49, 50, and 52), and a longer third antigen-binding loop (H3) folding over this area. For therapeutic applications the camelid-specific amino acid sequences in the framework have to be mutated to their human heavy chain variable domain equivalent, i.e. humanized. We performed this humanization exercise with Nanobodies of the subfamily that represents close to 80% of all dromedary-derived Nanobodies and investigated the effects on antigen affinity, solubility, expression yield, and stability. It is demonstrated that the humanization of Nanobody-specific residues outside framework-2 are neutral to the Nanobody properties. Surprisingly, the Glu-49 → Gly and Arg-50 → Leu humanization of hallmark amino acids generates a single domain that is more stable though probably less soluble. The other framework-2 substitutions, Phe-42 → Val and Gly/Ala-52 → Trp, are detrimental for antigen affinity, due to a repositioning of the H3 loop as shown by their crystal structures. These insights were used to identify a soluble, stable, well expressed universal humanized Nanobody scaffold that allows grafts of antigen-binding loops from other Nanobodies with transfer of the antigen specificity and affinity. Minimizing the size of antigen-binding entities from a multidomain protein such as a monoclonal antibody to a single-chain variable fragment or even a single domain has been one of the primary goals of antibody engineering. For drug therapy, these smaller formats can be beneficial in various aspects such as immunogenicity, biodistribution, renal clearance, serum half-life, tissue penetration, and target retention. However, the minimal sized antibody fragments need to retain sufficiently high antigen specificity and affinity, be expressed in high yields, and should have a low tendency to aggregate so as to maintain maximal potency and reduce possible risks of immunogenicity. Moreover functionality in adverse environments such as high concentrations of denaturant or elevated temperatures, and a concomitant increased shelf-life are additional assets. A significant proportion of the functional antibodies within species of the Camelidae are devoid of light chains. These immunoglobulins are referred to as heavy-chain antibodies (1Hamers-Casterman C. Atarhouch T. Muyldermans S. Robinson G. Hamers C. Songa E.B. Bendahman N. Hamers R. Nature.. 1993; 363: 446-448Google Scholar), and their antigen-binding fragment is reduced to a single domain (referred to as VHH or Nanobody), with a molecular size of only ∼15 kDa, which is smaller in comparison to single-chain variable fragment fragments (30 kDa), Fab fragments (60 kDa), and whole antibodies (150 kDa). All Nanobodies belong to the same sequence family, closely related to that of the human VH 3The abbreviations used are: VH, heavy chain variable domain; LDA, ligation during amplification protocol; GdmCl, guanidinium ch
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
ExPASy: the proteomics server for in-depth protein knowledge and analysis
Gasteiger, E. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg563 · Cited by 5,595
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
Self-citation[14]Determination and analysis of urea and guanidine hydrochloride denaturation curves
Pace, C. N. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)31045-0 · Cited by 2,258
Protein structure: A practical approach
(1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90136-y · Cited by 1,988
Myers, J. K., Nick Pace, C., & Martin Scholtz, J. (1995) · Protein Science · doi:10.1002/pro.5560041020 · Cited by 1,720
Likelihood-enhanced fast translation functions
McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C., & Read, R. J. (2005) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905001617 · Cited by 1,639
Santoro, M. M., & Bolen, D. W. (1988) · Biochemistry · doi:10.1021/bi00421a014 · Cited by 1,582
Likelihood-enhanced fast rotation functions
Storoni, L. C., McCoy, A. J., & Read, R. J. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444903028956 · Cited by 1,172
Ward, E. S., Güssow, D., Griffiths, A. D., Jones, P. T., & Winter, G. (1989) · Nature · doi:10.1038/341544a0 · Cited by 1,003
Isolation of high affinity human antibodies directly from large synthetic repertoires.
Griffiths, A. D., Williams, S. C., Hartley, O., Tomlinson, I. M., Waterhouse, P., Crosby, W. L., Kontermann, R. E., Jones, P. T., Low, N. M., & Allison, T. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06626.x · Cited by 962
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809
Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies
Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R., & Muyldermans, S. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01062-4 · Cited by 768
Self-citationA Versatile Nanotrap for Biochemical and Functional Studies with Fluorescent Fusion Proteins
Rothbauer, U., Zolghadr, K., Muyldermans, S., Schepers, A., Cardoso, M. C., & Leonhardt, H. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700342-mcp200 · Cited by 677
Self-citationMolecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
De Genst, E., Silence, K., Decanniere, K., Conrath, K., Loris, R., Kinne, J., Muyldermans, S., & Wyns, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505379103 · Cited by 676
Self-citationSingle‐domain antibody fragments with high conformational stability
Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F., Heremans, K., Frenken, L. G. J., Muyldermans, S., Wyns, L., & Matagne, A. (2002) · Protein Science · doi:10.1110/ps.34602 · Cited by 638
Self-citationTomlinson, I. M., Walter, G., Marks, J. D., Llewelyn, M. B., & Winter, G. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90223-7 · Cited by 603
Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme
Desmyter, A., Transue, T. R., Ghahroudi, M. A., Dao Thi, M.-H., Poortmans, F., Hamers, R., Muyldermans, S., & Wyns, L. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0996-803 · Cited by 522
Self-citationMuyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J. A. R. G., & Hamers, R. (1994) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/7.9.1129 · Cited by 494
Self-citationMeasuring and increasing protein stability
PACE, C. (1990) · Trends in Biotechnology · doi:10.1016/0167-7799(90)90146-o · Cited by 468
Efficient Cancer Therapy with a Nanobody-Based Conjugate
Cortez-Retamozo, V., Backmann, N., Senter, P. D., Wernery, U., De Baetselier, P., Muyldermans, S., & Revets, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3935 · Cited by 382
Self-citationEnergetics of complementary side chain packing in a protein hydrophobic core
Kellis, J. T., Nyberg, K., & Fersht, A. R. (1989) · Biochemistry · doi:10.1021/bi00437a058 · Cited by 347
β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae
Conrath, K. E., Lauwereys, M., Galleni, M., Matagne, A., Frère, J.-M., Kinne, J., Wyns, L., & Muyldermans, S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2807-2812.2001 · Cited by 347
Self-citationClarke, J., & Fersht, A. R. (1993) · Biochemistry · doi:10.1021/bi00067a022 · Cited by 343
Muyldermans, S., Cambillau, C., & Wyns, L. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01790-x · Cited by 322
Self-citationNguyen, V. K., Hamers, R., Wyns, L., & Muyldermans, S. (2000) · The EMBO Journal · doi:10.1093/emboj/19.5.921 · Cited by 299
Self-citationA camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme
Dumoulin, M., Last, A. M., Desmyter, A., Decanniere, K., Canet, D., Larsson, G., Spencer, A., Archer, D. B., Sasse, J., Muyldermans, S., et al. (2003) · Nature · doi:10.1038/nature01870 · Cited by 246
Self-citationSaerens, D., Pellis, M., Loris, R., Pardon, E., Dumoulin, M., Matagne, A., Wyns, L., Muyldermans, S., & Conrath, K. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.038 · Cited by 246
Self-citationHarmsen, M. M., Ruuls, R. C., Nijman, I. J., Niewold, T. A., Frenken, L. G. J., & de Geus, B. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00081-x · Cited by 217
Huang, L., Reekmans, G., Saerens, D., Friedt, J.-M., Frederix, F., Francis, L., Muyldermans, S., Campitelli, A., & Hoof, C. V. (2005) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2004.11.016 · Cited by 215
Self-citationHumanization of murine monoclonal antibodies through variable domain resurfacing.
Roguska, M. A., Pedersen, J. T., Keddy, C. A., Henry, A. H., Searle, S. J., Lambert, J. M., Goldmacher, V. S., Blättler, W. A., Rees, A. R., & Guild, B. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.3.969 · Cited by 201
Biophysical Properties of Camelid VHH Domains Compared to Those of Human VH3 Domains
Ewert, S., Cambillau, C., Conrath, K., & Plückthun, A. (2002) · Biochemistry · doi:10.1021/bi011239a · Cited by 184
Self-citationBarthelemy, P. A., Raab, H., Appleton, B. A., Bond, C. J., Wu, P., Wiesmann, C., & Sidhu, S. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708536200 · Cited by 179
Padlan, E. A. (1991) · Molecular Immunology · doi:10.1016/0161-5890(91)90163-e · Cited by 169
Desmyter, A., Decanniere, K., Muyldermans, S., & Wyns, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102107200 · Cited by 168
Self-citationExperimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor
Baral, T. N., Magez, S., Stijlemans, B., Conrath, K., Vanhollebeke, B., Pays, E., Muyldermans, S., & De Baetselier, P. (2006) · Nature Medicine · doi:10.1038/nm1395 · Cited by 166
Self-citationDecanniere, K., Desmyter, A., Lauwereys, M., Ghahroudi, M. A., Muyldermans, S., & Wyns, L. (1999) · Structure · doi:10.1016/s0969-2126(99)80049-5 · Cited by 164
Self-citation‘Camelising’ human antibody fragments: NMR studies on VH domains
Davies, J., & Riechmann, L. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)80432-x · Cited by 158
Davies, J., & Riechmann, L. (1996) · Protein Engineering Design and Selection · doi:10.1093/protein/9.6.531 · Cited by 155
The crystal structure of a llama heavy chain variable domain
Spinelli, S., Frenken, L. A. M., Bourgeois, D., de Ron, L., Bos, W., Verrips, T. C., Anguille, C., Cambillau, C., & TEGONI, M. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0996-752 · Cited by 149
Crystal Structure of HEL4, a Soluble, Refoldable Human VH Single Domain with a Germ-line Scaffold
Jespers, L. S., Schön, O., James, L. C., Veprintsev, D. B., & Winter, G. P. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.013 · Cited by 134
Saerens, D., Frederix, F., Reekmans, G., Conrath, K., Jans, K., Brys, L., Huang, L., Bosmans, E., Maes, G., Borghs, G., et al. (2005) · Analytical Chemistry · doi:10.1021/ac051092j · Cited by 125
Self-citationTanha, J., Dubuc, G., Hirama, T., Narang, S. A., & MacKenzie, C. R. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00027-3 · Cited by 124
Conrath, K., Vincke, C., Stijlemans, B., Schymkowitz, J. W. H., Decanniere, K., Wyns, L., Muyldermans, S., & Loris, R. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.04.050 · Cited by 120
Self-citationAires‐da‐Silva, F., Santa‐Marta, M., Freitas‐Vieira, A., Mascarenhas, P., Barahona, I., Moniz‐Pereira, J., Gabuzda, D. H., & Gonçalves, J. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.04.062 · Cited by 91
Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease
Martin, F., Volpari, C., Steinkühler, C., Dimasi, N., Brunetti, M., Biasiol, G., Altamura, S., Cortese, R., Francesco, R. D., & Sollazzo, M. (1997) · Protein Engineering Design and Selection · doi:10.1093/protein/10.5.607 · Cited by 89
Tetrameric and Homodimeric Camelid IgGs Originate from the Same IgH Locus
Achour, I., Cavelier, P., Tichit, M., Bouchier, C., Lafaye, P. J., & Rougeon, F. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2001 · Cited by 87
Optimal Design Features of Camelized Human Single-domain Antibody Libraries
Tanha, J., Xu, P., Chen, Z., Ni, F., Kaplan, H. A., Narang, S. A., & MacKenzie, C. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100770200 · Cited by 82
Jung, S. C., Spinelli, S., Schimmele, B., Honegger, A., Pugliese, L., Cambillau, C., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4665 · Cited by 68
Riechmann, L. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0373 · Cited by 57
Characteristics of human antibody repertoires following active immune responses in vivo
Ohlin, M., & Borrebaeck, C. A. K. (1996) · Molecular Immunology · doi:10.1016/0161-5890(96)00018-1 · Cited by 51
Degenerate interfaces in antigen-antibody complexes
Decanniere, K., Transue, T. R., Desmyter, A., Maes, D., Muyldermans, S., & Wyns, L. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.5075 · Cited by 51
Self-citationNon-stochastic utilization of Ig V region genes in unselected human peripheral B cells
Huang, S., Jiang, R., Glas, A. M., & MILNER, E. C. B. (1996) · Molecular Immunology · doi:10.1016/0161-5890(95)00162-x · Cited by 42
Chen, Z. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.4.1126 · Cited by 31
Voordijk, S., Hansson, T., Hilvert, D., & van Gunsteren, W. F. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3890 · Cited by 23
Research works printed but not linked: 2
- Roguska, 1994, Proc. Natl. Acad. Sci. U. S. A., 91, 969
- De Genst, 2006, Proc. Natl. Acad. Sci. U. S. A., 103, 4586
Cited by
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
Self-citationStructure and function of immunoglobulins
Schroeder, H. W., & Cavacini, L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.046 · Cited by 1,905
Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells
Scott, C. L., Zheng, F., De Baetselier, P., Martens, L., Saeys, Y., De Prijck, S., Lippens, S., Abels, C., Schoonooghe, S., Raes, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms10321 · Cited by 860
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Self-citationSingle domain antibodies: promising experimental and therapeutic tools in infection and immunity
Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., Cauerhff, A., Danquah, W., Rissiek, B., Scheuplein, F., et al. (2009) · Medical Microbiology and Immunology · doi:10.1007/s00430-009-0116-7 · Cited by 513
Metadata
- Authors
- Vincke, C., Loris, R., Saerens, D., Martinez-Rodriguez, S., Muyldermans, S., & Conrath, K.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 284
- Issue
- 5
- Pages
- 3273-3284
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2053319140
- Cited by
- 572
- References
- 56
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4306 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.